# Hyasynth Biologicals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/hyasynth-biologicals

- Industry: Healthcare
- Headquarters: Montreal, Canada
- Website: www.hyasynthbio.com
- Total disclosed funding: $2.1M
- Latest round: Seed (Nov 30, 2017)
- Investors on record: 6

## About

Hyasynth Biologicals Inc. develops and produces cannabinoid ingredients via a novel biosynthetic process, providing a sustainable and scalable alternative to traditional agricultural methods.Founded in 2014 in Montreal, Canada, Hyasynth Biologicals Inc. specializes in the biosynthesis of cannabinoids. The company has raised USD 2.5 mn in VENTURE DEBT financing in December 2021, led by Organigram Holdings Inc. With a total of 12 deals, the company continues to innovate in its sector. The founding team includes Alex Campbell, Kevin Chen, Shoham Mookerjee, and Zach Wiltshire, with Kevin Chen currently serving as CEO.Hyasynth Bio specializes in the development and production of cannabinoid ingredients through a novel biosynthetic process. Their core product offerings include a range of cannabinoids, synthesized using proprietary yeast fermentation technology, addressing the increasing demand for sustainable production. The company supplies products to various industries, including pharmaceuticals, nutraceuticals, and consumer goods, primarily in North America and Europe, catering to clients such as pharmaceutical companies and health product manufacturers.Hyasynth Bio generates revenue through strategic partnerships and direct sales of its cannabinoid products, engaging in B2B transactions. Clients purchase cannabinoid ingredients under agreements that outline pricing and delivery terms, potentially involving long-term supply contracts or one-off sales. The structure of these transactions includes volume discounts for larger orders or tiered pricing based on cannabinoid type and purity, establishing the company as a key player in the synthetic cannabinoid market with flagship high-purity offerings.In December 2021, Hyasynth Biologicals Inc. raised USD 2.5 mn in VENTURE DEBT financing to support its expansion efforts. The company plans to design and launch new products, although specific release dates are not disclosed. Additionally, Hyasynth aims to expand into new geographic markets, particularly targeting regions within Europe and North America. The recent funding will facilitate these initiatives, enabling the company to enhance its production capabilities and broaden its market reach.

## Funding rounds

- Seed, Nov 30, 2017, $0.8M — SOSV, Anges Quebec, Hedgewood
- Seed, Jul 27, 2017, $0.8M — SOSV, RebelBio, InnoStart Capital
- Seed, Jun 29, 2015, $0.5M — SOSV
- Series A, Apr 30, 2015 — SOSV
- Seed, May 20, 2014, $0.1M — SOSV, IndieBio

## Investors

- SOSV (https://capitalatlas.ai/funds/sosv) — Seed, Series A
- IndieBio (https://capitalatlas.ai/funds/indiebio) — Seed
- RebelBio — Seed
- InnoStart Capital — Seed
- Anges Quebec — Seed
- Hedgewood — Seed